Conditions: Melanoma
Keywords: ASCI Dacarbazine Cancer immunotherapeutic MAGE-A3 Malignant melanoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 48
Healthy volunteers: no

Brief summary:
The purpose of this clinical trial is to find out how successfully, patients with progressive metastatic cutaneous melanoma, are able to develop an immune response to injections with the immunotherapeutic product GSK1572932A when given in combination with dacarbazine and evaluate the safety of this combination.

Detailed description:
This Protocol Posting has been updated following amendment 3, dated 16 October 2009. The sections impacted are :

* Enrollment, number of subjects
* Outcome measures
* Exclusion criteria

Arms:
arm 1: All patients are to receive the same treatment consisting of 24 injections of the immunotherapeutic GSK2132231A combined with a course of 8 cycles of dacarbazine given at the beginning of the treatment

Interventions: intervention 1: Immunotherapeutic GSK2132231A intervention 2: Dacarbazine
Intervention descriptions: intervention 1: Intramuscular administration intervention 2: Intravenous administration Chemotherapy

Protocol document: